Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where V. Gunaseelan is active.

Publication


Featured researches published by V. Gunaseelan.


International Journal of Radiation Oncology Biology Physics | 2010

Higher Chest Wall Dose Results in Improved Locoregional Outcome in Patients Receiving Postmastectomy Radiation

J.E. Panoff; Cristiane Takita; Judith Hurley; Isildinha M. Reis; Wei Zhao; Steven E. Rodgers; V. Gunaseelan; Jean L. Wright

PURPOSE Randomized trials demonstrating decreased locoregional recurrence (LRR) and improved overall survival (OS) in women receiving postmastectomy radiation therapy (PMRT) used up to 50 Gy to the chest wall (CW), but in practice, many centers boost the CW dose to ≥60 Gy, despite lack of data supporting this approach. We evaluated the relationship between CW dose and clinical outcome. METHODS AND MATERIALS We retrospectively reviewed medical records of 582 consecutively treated patients who received PMRT between January 1999 and December 2009. We collected data on patient, disease, treatment characteristics, and outcomes of LRR, progression-free survival (PFS) and OS. RESULTS Median follow-up from the date of diagnosis was 44.7 months. The cumulative 5-year incidence of LRR as first site of failure was 6.2%. CW dose for 7% (43 patients) was ≤50.4 Gy (range, 41.4-50.4 Gy) and 93% received >50.4 Gy (range, 52.4-74.4 Gy). A CW dose of >50.4 Gy vs. ≤50.4 Gy was associated with lower incidence of LRR, a 60-month rate of 5.7% (95% confidence interval [CI], 3.7-8.2) vs. 12.7% (95% CI, 4.5-25.3; p = 0.054). Multivariate hazard ratio (HR) for LRR controlling for race, receptor status, and stage was 2.62 (95% CI, 1.02-7.13; p = 0.042). All LRR in the low-dose group occurred in patients receiving 50 to 50.4 Gy. Lower CW dose was associated with worse PFS (multivariate HR, 2.73; 95% CI, 1.64-4.56; p < 0.001) and OS (multivariate HR, 3.88; 95% CI, 2.16-6.99; p < 0.001). CONCLUSIONS The addition of a CW boost above 50.4 Gy resulted in improved locoregional control and survival in this cohort patients treated with PMRT for stage II-III breast cancer. The addition of a CW boost to standard-dose PMRT is likely to benefit selected high-risk patients. The optimal technique, target volume, and patient selection criteria are unknown. The use of a CW boost should be studied prospectively, as has been done in the setting of breast conservation.


International Journal of Radiation Oncology Biology Physics | 2010

Relationship between Nodal Stage, Post Mastectomy Radiation Field Selection, and Clinical Outcome after Neoadjuvant Chemotherapy for Breast Cancer

Jean L. Wright; Isildinha M. Reis; Wei Zhao; V. Gunaseelan; Mecker Moller; Cristiane Takita; Judith Hurley


International Journal of Radiation Oncology Biology Physics | 2009

Locoregional Outcomes in an Inner City Underserved Population of Triple-negative Breast Cancer Patients Receiving Induction Therapy with Platinum Salts and Docetaxel

Jean L. Wright; Isildinha M. Reis; Cristiane Takita; Mark D. Pegram; Steven E. Rodgers; J.D. Leone; V.D. Guardiola; V. Gunaseelan; Judith Hurley


International Journal of Radiation Oncology Biology Physics | 2012

Assessment of Prognostic Features in Treatment Decision for Ductal Carcinoma In Situ of the Breast

Cristiane Takita; Deukwoo Kwon; Jean L. Wright; V. Gunaseelan; Isildinha M. Reis


International Journal of Radiation Oncology Biology Physics | 2012

The Role of Hormone Therapy for Node Negative Breast Cancer Patients With ER + Tumors 1 cm or Less

J.E. Panoff; Tulay Koru-Sengul; Feng Miao; V. Gunaseelan; Jean L. Wright; Cristiane Takita


International Journal of Radiation Oncology Biology Physics | 2011

Triple Negative but not HER2 Positive Breast Cancer Subtype is Associated with Higher Locoregional Recurrence after Breast-conserving Therapy and Modern Systemic Therapy

Cristiane Takita; Isildinha M. Reis; Feng Miao; K. LaFave; V. Gunaseelan; Jean L. Wright


Fuel and Energy Abstracts | 2011

Triple Negative but not HER2 Positive Breast Cancer Subtype is Associated with Higher Locoregional R

Cristiane Takita; Isildinha M. Reis; Fuyou Miao; K. E. LaFave; V. Gunaseelan; Joanne L. Wright


International Journal of Radiation Oncology Biology Physics | 2010

Interval of up to 16 Weeks Between Mastectomy and Radiation Does Not Impair Locoregional Outcome in Patients Receiving Neoadjuvant Chemotherapy

Shiv Desai; Isildinha M. Reis; Wei Zhao; Cristiane Takita; Judith Hurley; V. Gunaseelan; Steven E. Rodgers; Jean L. Wright


International Journal of Radiation Oncology Biology Physics | 2010

Outcomes of Breast Conserving Therapy for DCIS in a Minority Population at University of Miami

G.A. Hobeika; Gail Walker; Jean L. Wright; Aaron H. Wolfson; O. Mahmoud; B.J. Greenfield; V. Gunaseelan; M.A. Wahab; Arnold M. Markoe; Cristiane Takita


Fuel and Energy Abstracts | 2010

Relationship between Nodal Stage, Post Mastectomy Radiation Field Selection, and Clinical Outcome af

Joanne L. Wright; Isildinha M. Reis; Wulue Zhao; V. Gunaseelan; M. Oliver Moller; Cristiane Takita; James B. Hurley

Collaboration


Dive into the V. Gunaseelan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge